SOURCE: HealthSonix, Inc.

April 11, 2007 09:25 ET

HealthSonix to Conduct Joint Clinical Studies With Major Drug Manufacturers

IRVINE, CA -- (MARKET WIRE) -- April 11, 2007 -- HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) announced that it is working closely with a number of major pharmaceutical companies, with a view to expand clinical claims and to address the guidelines published by the American College of Rheumatology in the treatment of patients with osteo and rheumatoid arthritis.

The draft recommendations tabled at the recent World Congress on Osteoarthritis suggest that optimal management of patients with osteoarthritis of the hip and knee require a combination on non-pharmacologic and pharmacologic modalities of treatment in most patients. Physicians have always been aware of these guidelines, but were limited in their choices of "non-pharmacologic" treatments.

HealthSonix offers a variety of proven non-pharmacologic therapies with its proprietary sound pressure wave treatments, such as AquaSonix Therapy -- a therapeutic water program that combines company's sound pulse technology with Arthritis Foundation's low impact exercises in warm water therapy pools.

The proprietary sound pulse technology is believed to work by stimulating mechanoreceptors in the skin, which in turn communicate with the brain and block pain messages from getting through (gate control theory of pain); by creating an exercise effect in the muscles, which encourages the production and release of endorphins, the body's natural pain killers.

The objective of the joint clinical trials is to scientifically confirm the efficacy of combined therapies. "We anticipate that clinical trials will show that AquaSonix Therapy when combined with certain medications will significantly reduce pain, improve function and further improve the patient's quality of life, when compared to patients taking medications alone," explained Dieter Doederlein, Vice president of Business Development.

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pulses are 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive and have no known side effects.

More information regarding HealthSonix and its products and services can be found on the World Wide Web at: or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information

  • HealthSonix, Inc.